Cardiff Oncology vs Exicure
CRDF and XCUR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRDF and XCUR compare
Cardiff Oncology is the larger company, worth 9.6 times as much as Exicure ($65.3M against $6.8M).
Cardiff Oncology scores higher on the StockData Score (7 against 4 for Exicure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRDF | XCUR |
|---|---|---|
| Size and price | ||
| Market cap | $65.3M | $6.8M |
| Share price | $0.839 | $1.04 |
| Change, 1 year | −59.3% | −71.3% |
| Change, 5 years | −85.0% | −98.6% |
| Beta (5Y) | 1.58 | 1.27 |
| Employees | 31 | 8 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 128× | – |
| P/B | 2.5× (better) | 7.0× |
| Growth | ||
| Revenue growth (TTM) | −7.0% | – |
| Revenue growth, 5Y average | 10.1% | – |
| Profitability | ||
| Operating margin | −8320% | – |
| Net margin | −7884% | – |
| Return on equity | −94.1% (better) | −168% |
| Return on invested capital | – | −4377% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.30 (better) | 0.56 |
| Altman Z-score | −16.24 (better) | −27.38 |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 24.2% | 2.1% |
| Held by insiders | 4.9% | 92.6% |
| Insider net buying, 12 months | $1.1M (better) | −$11.6M |
| Short interest, % of float | 16.6% | 10.8% |
Go deeper
- CRDF stock overview
- CRDF income statement
- CRDF valuation and score
- XCUR stock overview
- XCUR income statement
- XCUR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.